VS
iShares Genomics Immunology and Healthcare Index ETF (XDNA) and BMO Global Health Care Fund Active ETF Series (ZGHC) offer distinct profiles for Canadian ETF investors. A direct comparison shows that XDNA focuses its top 3 sector exposures on Healthcare, while ZGHC leans towards Healthcare, Consumer Non-Cyclicals, and Consumer Cyclicals. When evaluating costs, XDNA features a management fee (MER) of 0.39%, compared to 1.02% for ZGHC. Performance-wise, XDNA has returned 59.1% year-to-date with +$9 M in net flows, whereas ZGHC is at 11.87% with +$13 M. Use the comparison tool below to benchmark these funds across top 10 holdings, yield, sector weights and historical returns.
NAV Performance and Flows
Key Data
Compare
XDNA
ZGHC
| AuM | $19.17 M | $16.74 M |
| Management Fees | 0.39% | 1.02% |
| Exp. ratio | 0.44% | 0.82% |
| Tracking Difference | -1.05% | - |
Historical performance and flows
As of October 23, 2026
| 1M | 3M | YTD | 1Y | 3Y | ||
|---|---|---|---|---|---|---|
| Perf. | XDNA | -0.63% | +24.74% | +59.10% | +66.96% | +139.16% |
ZGHC | +4.09% | +5.98% | +11.87% | +18.09% | +38.49% | |
| Flows | XDNA | +$3 M | +$7 M | +$9 M | +$9 M | +$9 M |
ZGHC | +$0 M | +$4 M | +$13 M | +$14 M | +$15 M |
XDNA vs ZGHC exposure
Countries
XDNA
USA
63.68%
Germany
7.53%
Other
28.79%
ZGHC
USA
78.05%
Switzerland
8.47%
Other
13.47%
Sectors
XDNA
Healthcare
99.80%
ZGHC
Healthcare
98.21%
As of October 23, 2026
Top 10 Holdings
XDNA
Moderna, Inc.
8.85%
Twist Bioscience Corp.
6.01%
Revolution Medicines, Inc.
4.12%
Bayer AG
4.08%
Genmab A/S
4.00%
Regeneron Pharmaceuticals, Inc.
3.76%
Merck & Co., Inc.
3.66%
Vertex Pharmaceuticals, Inc.
3.65%
Incyte Corp.
3.60%
Takeda Pharmaceutical Co., Ltd.
3.49%
ZGHC
Eli Lilly & Co.
10.09%
Merck & Co., Inc.
7.50%
Johnson & Johnson
7.20%
UnitedHealth Group, Inc.
6.94%
AstraZeneca PLC
6.38%
AbbVie, Inc.
5.45%
argenx SE
5.06%
Abbott Laboratories
4.38%
Gilead Sciences, Inc.
4.30%
Novartis AG
3.48%
Diversification
XDNA
Total weight of top 10 holdings out of 47 total
45.23%
ZGHC
Total weight of top 10 holdings out of 118 total
60.77%
Characteristics
Compare
XDNA
ZGHC
| Provider | iShares | BMO |
| Management | Passively managed | Actively managed |
| Benchmark | NYSE FactSet Global Genomics and Immuno Biopharma NR Index - CAD | - |
| Replication Method | Direct (Physical) | - |
| Asset Class | Equity | Equity |
| Dividend Policy | Distributing | Distributing |
| Trailing 12m distribution yield | 0.20% | 0.00% |
| Meets ESG criteria | No | No |
| Inception Date | April 26, 2022 | June 26, 2023 |
Frequently asked questions about XDNA and ZGHC
Which ETF has performed better year to date: XDNA or ZGHC?
As of October 23, 2026, XDNA has returned 59.10% year to date, while ZGHC has returned 11.87%. XDNA is ahead on YTD performance.
Which ETF is larger by assets under management: XDNA or ZGHC?
As of October 23, 2026, XDNA manages $19.17 M in assets, while ZGHC manages $16.74 M. XDNA is the larger fund by AUM.
How are XDNA and ZGHC managed?
XDNA is passively managed by iShares. It tracks the NYSE FactSet Global Genomics and Immuno Biopharma NR Index - CAD benchmark. ZGHC is actively managed by BMO. It does not track an index.
What sectors do XDNA and ZGHC emphasize?
XDNA is most exposed to Healthcare. ZGHC is most exposed to Healthcare, Consumer Non-Cyclicals, and Consumer Cyclicals.
Which ETF is attracting more investor flows: XDNA or ZGHC?
Year to date, XDNA has seen +$9.50 M in net flows, compared with +$12.55 M for ZGHC. ZGHC has attracted more net investor money so far.
How do the fees of XDNA and ZGHC compare?
XDNA has an expense ratio of 0.44%, while ZGHC has an expense ratio of 0.82%.
What are the top holdings of XDNA and ZGHC?
XDNA's largest holdings include Moderna, Inc., Twist Bioscience Corp., and Revolution Medicines, Inc.. ZGHC's top holdings include Eli Lilly & Co., Merck & Co., Inc., and Johnson & Johnson.
Which ETF is more diversified: XDNA or ZGHC?
XDNA holds 47 securities, while ZGHC holds 116. On holdings count, ZGHC is the more diversified portfolio.
Recent articles about XDNA and ZGHC
The ETF Market Canada is brought to you by Cboe in partnership with Trackinsight SA who is providing all the data, analysis and editorial content on this site. Unless explicitly stated as such, any information that you receive is not real-time.
All content on the ETF Market Canada is for your general information use only, Cboe is not responsible for any use of content by you outside this scope. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by Cboe and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
All content on the ETF Market Canada is for your general information use only, Cboe is not responsible for any use of content by you outside this scope. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by Cboe and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.